TMC207LEP3001 (LIGHT), A Phase 3, Multicenter, Open-label, Rater-blind, Active- controlled Study to Evaluate the Efficacy and Safety of Bedaquiline for the Treatment of Multibacillary Leprosy When Combined With Rifampicin and Clofazimine, 2025- 2028, Grant Amount $ 427,040, Jansens, Johnson & Johnson